Global Fuchs Endothelial Corneal Dystrophy Market Size To Grow USD 360 Billion by 2032 | CAGR of 7.7%

Category: Healthcare

RELEASE DATE Apr 2023
REPORT ID SI1711

A PHP Error was encountered

Severity: Notice

Message: Undefined variable: table

Filename: press/detail.php

Line Number: 118

Backtrace:

File: /home/admin/web/sphericalinsights.com/public_html/application/views/press/detail.php
Line: 118
Function: _error_handler

File: /home/admin/web/sphericalinsights.com/public_html/application/views/layouts/master_header_footer.php
Line: 720
Function: view

File: /home/admin/web/sphericalinsights.com/public_html/application/controllers/Press.php
Line: 89
Function: view

File: /home/admin/web/sphericalinsights.com/public_html/index.php
Line: 295
Function: require_once

Global Fuchs Endothelial Corneal Dystrophy (FECD) Market To Grow $360 Billion by 2032

According to a research report published by Spherical Insights & Consulting, Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Size is to grow from USD 170 Billion in 2022 to USD 360 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period.

 

Global Fuchs Endothelial Corneal Dystrophy (FECD) Market

Get more details on this report -

Request Free Sample PDF

Browse key industry insights spread across 200 pages with 100 market data tables and figures & charts from the report on “Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Size, Share, and COVID-19 Impact Analysis, By Treatment (Medication, Surgery, Others), By Diagnosis (Cornea Examination and Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count, Others), By End-Users (Hospital, Specialty Clinics, Homecare, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022– 2032”. Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/fuchs-endothelial-corneal-dystrophy-fecd-market

 

Fuchs endothelial corneal dystrophy (FECD) is another term for corneal degeneration. Affected is the thin cell layer that lines the back of the tissue layer. The term "endothelium" is frequently used to describe this layer. When these cells begin to disappear, illness rapidly follows. The cells help to remove the excess fluid from the tissue layer. As more tissues decline the tissue layer fills with fluid, causing edema and an unclear cornea. A form of endothelial dystrophy that affects the tissue layer on the front surface of the attention is Fuchs endothelial dystrophy. A characteristic of Fuchs Endothelial Corneal Dystrophy in elderly adults is bilateral, asymmetrical, and slowly contracting corneal edema. Currently, there are several therapy options for FECD, including drugs, corneal transplantation, and Descemet membrane endothelial keratoplasty (DMEK). The majority of the market share is accounted for by corneal transplantation, which is the most frequently prescribed treatment for fuchs endothelial corneal dystrophy.

 

The fuchs endothelial corneal dystrophy market is driven by several reasons, including the fact that women are more likely than males to develop this condition, which often affects persons over the age of 50. The market for treatments for Fuchs' endothelial corneal dystrophy will benefit from increased research into cellular therapy strategies and rising demand for eye care over the projected period. Furthermore, many people might not be aware of global fuchs endothelial corneal dystrophy, its signs or symptoms, or the current therapies. This may cause the disease's identification and treatment to be delayed, which may lead to severe difficulties and vision impairment.

 

COVID 19 Impact

The pandemic has led to delays in the diagnosis and treatment of fuchs endothelial corneal dystrophy, as many healthcare facilities have prioritized COVID-19 cases over non-urgent procedures. This has resulted in longer wait times for patients seeking treatment, which may lead to worse outcomes in some cases. The pandemic has disrupted global supply chains, leading to shortages of medical equipment, medications, and other supplies needed for the treatment of this illness. This has resulted in increased costs and reduced availability of some treatments. Furthermore, many patients have been reluctant to seek medical care during the pandemic, either due to concerns about exposure to COVID-19 or because of restrictions on non-essential medical visits. This has led to a reduction in the number of patients seeking treatment for fuchs endothelial corneal dystrophy and other conditions. Overall, the COVID-19 pandemic has had a significant impact on the FECD market, leading to delays in diagnosis and treatment, disruptions in the supply chain, and changes in treatment approaches. However, as the pandemic is brought under control and healthcare systems adapt to the new environment, it is expected that the fuchs endothelial corneal dystrophy market will recover and continue to grow in the coming years.

 

The surgery segment is dominating the market with the largest market share during the forecast period.

Based on the treatment, the global fuchs endothelial corneal dystrophy market is classified into medication, surgery, and others. Among these, the surgery segment is dominating the market during the forecast period owing to the surgery involving replacing the damaged endothelium layer of the cornea with healthy donor tissue and is the most widely used treatment for fuchs endothelial corneal dystrophy. While Descemet membrane endothelial keratoplasty (DMEK) only transplants the cornea's thin inner layer, traditional corneal transplantation involves the replacement of the entire cornea.

 

The cornea examination and grading segment is influencing the market with the largest market share over the forecast period.

Based on the diagnosis, the global fuchs endothelial corneal dystrophy market is bifurcated into cornea examination and grading, corneal tomography, corneal pachymetry, corneal cell count, and others. Among these segments, cornea examination and grading are holding the largest market share over the forecast period, owing to due to the significance of identifying the disease's severity in selecting the best course of treatment.

 

The hospital segment is influencing the market share growth during the forecast period.

Based on the end users, the global fuchs endothelial corneal dystrophy market is bifurcated into hospitals, specialty clinics, home care, & others. Among these, the hospital segment is expected to grow the market during the forecast period, due to the reason that the majority of patients with advanced fuchs endothelial corneal dystrophy require surgical treatment, which is frequently carried out in a hospital setting.

 

North America is dominating the market with the largest market share during the forecast period

 

Global Fuchs Endothelial Corneal Dystrophy (FECD) Market

Get more details on this report -

Request Free Sample PDF

 

North America is dominating the market growth of fuchs endothelial corneal dystrophy due to there being many significant key players present, people having a lot of money to spend, and the healthcare system being well-established. Moreover, increasing the illness incidence may dominate the growth of the market.

 

Europe is the leading market for fuchs endothelial corneal dystrophy, and it will continue to grow shortly due to the growing influence of organ donation programs, availability of various treatment options and prevention strategies, and growing government focus on organ donation policies.

 

Major vendors in the Global Fuchs endothelial Corneal Dystrophy Market include Kowa Company, Ltd., Trefoil Therapeutics, AERIE PHARMACEUTICALS, INC., Price Vision Group, ProQR Therapeutics, Emmecell, Pfizer Inc., GlaxoSmithKline plc, Bausch Health Companies Inc., Bayer AG, Allergan, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Novartis AG, and others market players.

 

key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting and Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Recent Development

  • In November 2022, Aerie Pharmaceuticals, Inc. has been successfully acquired by Alcon, a leader in worldwide eye care committed to helping people to see brilliantly. Thanks to its expanding portfolio of supplied pharmaceuticals and development pipeline, Alcon is now more prevalent in the ophthalmic pharmaceutical sector.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Fuchs endothelial Corneal Dystrophy Market based on the below mentioned segments:

 

Global Fuchs endothelial Corneal Dystrophy Market, By Treatment

  • Medication
  • Surgery
  • Others

 

Global Fuchs endothelial Corneal Dystrophy Market, By Diagnosis

  • Cornea Examination and Grading
  • Corneal Tomography
  • Corneal Pachymetry
  • Corneal Cell Count
  • Others

 

Global Fuchs endothelial Corneal Dystrophy Market, By End Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

 

Fuchs endothelial Corneal Dystrophy Market, By Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies